SlideShare a Scribd company logo
1 of 27
Download to read offline
A S E M I N A R P R E S E N T A T I O N
B Y
B E N J A M I N G O O D L U C K C .
1 2 / 1 0 3 1
M I C R O B I O L O G Y
MICROBICIDES
INTRODUCTION
 HIV most often is spread through unprotected vaginal intercourse,
with women twice as likely as men to become infected. (UNAIDS,
2001)
 Women represent more than half (52 percent) of all people living
with HIV worldwide and account for nearly 60 percent of those with
HIV in sub-Saharan Africa. (Rossi and Collins, 2014)
 Efforts to promote abstinence, monogamy and the use of male
condoms have not been enough to stop the epidemic nor are these
approaches practical in many settings.
 A vaginal microbicide could potentially give women the means to
protect themselves against HIV.
2
WHAT ARE MICROBICIDES?
 Microbicides are products applied inside the vagina
or rectum to protect against sexually transmitted
infections (STIs) including human
immunodeficiency virus (HIV) through sex
(Lerner, 1994)
 Microbicides can be formulated as gels, creams,
films, or suppositories (Ramjee et al., 2001)
 Microbicides may or may not have spermicidal
activity (contraceptive effect) (Wilkinson et al.,
2002)
3
Fig 1. Various Microbicide products, showing;
vaginal gel, ring and film.
4
BRIEF HISTORY
 The idea for a microbicide-like product was first
proposed about 25 years ago by reproductive health
specialists and advocates who recognized the need
for female-controlled HIV prevention methods.
 One of the first products considered was the
spermicide nonoxynol-9, but clinical trials found it
neither safe nor effective against HIV (Wilkinson et
al., 2002)
 Trials of other so-called first generation microbicides
also yielded disappointing results.
5
HOW DO THEY WORK?
 There are different ways in which microbicides act to
prevent infection with genital pathogens.
 Some microbicides (e.g Carraguard®, Cyanoviran®,
cellulose sulphate, PRO 2000®) provide a physical
barrier that keeps HIV and other pathogens from
reaching the target cells.
 Another class of microbicides (e.g. Acidform®,
BufferGel®) act by enhancing the natural vaginal
defence mechanisms by maintaining an acidic pH,
which protects the vagina.
6
Cont.
 C31G and octoxynol-9 kill or disable pathogens by
stripping them of their outer covering.
 Another class of products e.g tenofovir (PMPA) acts
by preventing replication of the virus after it has
entered the cell (Karim, 2010)
7
Fig.2: Mechanism of Action
8
MICROBICIDES CLINICAL TRIALS
 There are three phases of clinical trials that a potential
mircobicide must pass through before it is judged effective
and safe.
1. Phase I involves a small number of volunteers to test the
safety of various doses
2. Phase II involves hundreds of volunteers to further assess
safety and, in some cases, positive responses
3. Phase III involves thousands of volunteers to test safety and
effectiveness
4. The Phase IIb trial, a recent innovation, is a larger variant of
the Phase II trial.
 Phase I tends to last between twelve and eighteen months,
whereas the final phase can take up to three or four years
(Microbicides Trials Network, 2013)
9
Fig.3: Process of Testing
10
 There are several different microbicide candidates
currently being studied. As of May 2013 there were
11 phase I trials, 1 phase I/II trial, and 4 phase III
trials. The current status of ongoing microbicide
trials can be found here (MTN, 2013)
 IPM027 (The Ring Study)
 MTN 020 (ASPIRE)
 CAPRISA 008
 FACTS 001
11
Product Clinical Trials Country Case Study Duration
Tenofovir
Vaginal
gel
CAPRISA 004
FACTS 001
(PhaseIII)
CAPRISA 008
(PhaseIIb)
South Africa
South Africa
South Africa
889 women
2900
women
889 women
Completed
2011-2015
2011-2015
Vaginal
Rings
ASPIRE(MTN-020)
(PhaseIII)
The Ring Study
(IPM 027)
(PhaseIII)
MTN-013/IPM 026
(PhaseI)
MTN-023/IPM 30
and MTN-
024/IPM31
(PhaseI)
Malawi, Uganda,
South Africa and
Zimbabwe
South Africa and
Uganda
United States
Malawi, Uganda,
South Africa and
Zimbabwe
3476 women
1650 women
Unknown
Adolescent
girls and
post-
menopausal
women
2012-2015
2012-
2015/2016
Completed
2012-2016
Table 1: Current Microbicides Clinical Trials
12
 Which microbicide trials have recently ended?
 CAPRISA 004
 This phase IIb trial assessed the safety and effectiveness of
tenofovir gel in 900 HIV-negative, sexually active women
between the ages of 18 and 40 years, living in South Africa.
Results for this trial were announced in July, 2010.
 The statistically significant results found:
1. Tenofovir gel reduced the risk of HIV infection by 39 percent
overall
2. Protective effect increased to 54 percent among women with
high gel adherence
 The CAPRISA 004 study was the first to provide proof of
concept for microbicides. The study found statistically
significant results showing microbicides can prevent the sexual
transmission of HIV (MTN, 2011)
13
 Researchers now are evaluating microbicide
products that incorporate ARV drugs, including
ARVs commonly used in HIV treatment.
 The most studied ARV-based microbicide is
tenofovir gel, which was found safe and effective in
reducing HIV risk in women who used it before and
after vaginal sex in a study called CAPRISA 004 but
not effective in another study known as VOICE,
which was designed to evaluate its daily use (as well
as daily use of either the oral ARV tablet tenofovir or
Truvada).
TENOFOVIR/VAGINAL GELS
14
Fig.4: Tenofovir Vaginal gel
15
Fig.5: Picture showing the oral ARV
tablet and the tenovovir vaginal gel
L-R:
Left: Oral ARV tablet
(tenofovir)
Right: Tenofovir Vaginal
gel
16
 As an alternative to vaginal gels, researchers are
evaluating other formulations, including paper-thin
quickdissolve vaginal films that after insertion would
melt away and disperse active drug to protect cells in
the vagina.
 Films are in the early phases of clinical testing.
VAGINAL FILMS
17
Fig.6: A paper-thin quick dissolving vaginal
film
18
VAGINAL RINGS
 Vaginal rings, flexible products that fit comfortably
inside the vagina and provide sustained delivery of
drugs over a period of time, are being tested in both
early phase studies and Phase III trials.
 Vaginal ring products are already used in many
countries to deliver hormonal contraception.
 For HIV prevention, the dapivirine ring is the first
vaginal ring – and the first HIV-prevention product
intended for monthly use – to enter efficacy testing.
19
Cont.
 Vaginal rings containing both an ARV
and a contraceptive are also being
developed that would potentially
provide women both HIV protection
and contraception in a single product.
Phase I trials began in 2014.
20
Fig.7: Vaginal Ring
21
RECTAL MICROBICIDES
 Although the majority of microbicide research has
focused on products to prevent HIV through vaginal
sex, anal sex is common among men who have sex
with men (MSM) and practiced by women around
the world.
 According to some estimates, the risk of infection
through anal sex is 20 times greater than vaginal sex
because the rectal lining, the mucosa, is thinner and
much more fragile than the lining of the vagina.
22
CONT.
 An important first step to the development of rectal
microbicides has been evaluating the rectal safety of
microbicides originally formulated as vaginal gels, in
particular, tenofovir gel.
 An early study found that the vaginal formulation of
tenofovir gel caused gastrointestinal side effects when
used in the rectum, so researchers tested a reformulated
version of the gel with less glycerin in a follow-up study
called MTN-007.
 That study found the reduced glycerin gel safe,
acceptable and better tolerated than the vaginal gel when
used in the rectum.
23
HOW IS IT FUNDED?
 In 2011 around $186 million was invested in microbicide
research and development (a 25 percent decrease on the
previous year).
 This decline has been associated with the cycle of funding
disbursement, rather than a decline in investment.
 About 95 percent of this money came from the public sector, 5
percent came from the philanthropic sector, and <1 percent
was accounted for by commercial companies (only $1 million).
 To ensure microbicides a
 re available to women in low- and middle-income countries,
profit margins would need to be low (UNAIDS, 2008)
24
CONCLUSION
 A safe and effective microbicide has potential to
become a key method of HIV prevention. As the
trials above demonstrate, microbicide research and
development brings us ever closer to having a
successful candidate.
 Any successful product would have to undergo
review and licensing by regulatory agencies before
becoming available to the public.
 It would take time to work out the best formulation
and dosage; find a suitable delivery method; and
distribute the product.
25
REFERENCES
 HIV Vaccines and Microbicides Resource Tracking Working Group
(2012) Investing to End the AIDS Epidemic: A New Era for HIV
Prevention Research & Development
 Karim, Q.A. (2010) ' Effectiveness and safety of tenofovir gel, an
antiretroviral microbicide, for the prevention of HIV infection in
women', Science 329(5996)
 Lerner S., (1994). Microbicides: a woman-controlled HIV
prevention method in the making. SIECUS : 22:10-3.
 Lisa Rossi and Clare Collins. 2014. “ Fact sheet about microbicides”.
Microbicides Trials Network, www.mtnstopshiv.org
 Microbicide Trials Network, (2011). MTN Statement on Decision to
Discontinue Use of Tenofovir Gel in VOICE, a Major HIV
Prevention Study in Women
 Microbicide Trials Network, (2013). Fact Sheet: Understanding the
results of VOICE
26
Cont.
 UNAIDS, (1996). International Working Group on Vaginal Microbicides,
Recommendations for the development of microbicides. AIDS, 10:1-6.
 Ramjee G, Gouws E, Andrews A, Myer L, Weber A.E., (2001). The
acceptability of a vaginal microbicides among South African men.
International Family planning Perspectives, 27:164-170.
 UNAIDS, (2001). AIDS epidemic update: Joint United Nations Programme
on HIV/AIDS and the World Health Organization.
 UNAIDS, (2008). Microbicides: challenges to development and
distribution.
 Wilkinson D, Tholandi M, Ramjee G, Rutherford GW., (2002). Nonoxynol-
9 spermicide for prevention of vaginally acquired HIV and other sexually
transmitted infections: systematic review and meta-analysis of randomised
controlled trials including more than 5000 women. Lancet Infectious
Diseases; 2:613-617
 World Health Organization, (2009). Regulatory issues in microbicide
development.
27

More Related Content

What's hot (20)

Blood coagulation
Blood coagulationBlood coagulation
Blood coagulation
 
Skeletal muscle relaxants
Skeletal muscle relaxantsSkeletal muscle relaxants
Skeletal muscle relaxants
 
Halothane by Dr. Aram Shah
Halothane by Dr. Aram ShahHalothane by Dr. Aram Shah
Halothane by Dr. Aram Shah
 
Ischemia repuefusion by momen
Ischemia repuefusion by momenIschemia repuefusion by momen
Ischemia repuefusion by momen
 
Hemostasis and coagulation of blood For M.Sc & Basic Medical Students by Pand...
Hemostasis and coagulation of blood For M.Sc & Basic Medical Students by Pand...Hemostasis and coagulation of blood For M.Sc & Basic Medical Students by Pand...
Hemostasis and coagulation of blood For M.Sc & Basic Medical Students by Pand...
 
Liposome
LiposomeLiposome
Liposome
 
Plasma volume expanders
Plasma volume expandersPlasma volume expanders
Plasma volume expanders
 
Liposome drug delivery system
Liposome drug delivery systemLiposome drug delivery system
Liposome drug delivery system
 
1 3-drug delivery systems
1 3-drug delivery systems1 3-drug delivery systems
1 3-drug delivery systems
 
Pharmacokinetics
PharmacokineticsPharmacokinetics
Pharmacokinetics
 
Pathology (microscopic feature of some tumors)
Pathology (microscopic feature of some tumors)Pathology (microscopic feature of some tumors)
Pathology (microscopic feature of some tumors)
 
Heparin
HeparinHeparin
Heparin
 
PHARMACOLOGY OF LOCAL ANESTHESIA
PHARMACOLOGY OF LOCAL ANESTHESIA PHARMACOLOGY OF LOCAL ANESTHESIA
PHARMACOLOGY OF LOCAL ANESTHESIA
 
INTRANASAL ROUTE DELIVERY SYSTEM
INTRANASAL ROUTE DELIVERY SYSTEMINTRANASAL ROUTE DELIVERY SYSTEM
INTRANASAL ROUTE DELIVERY SYSTEM
 
Drugs.uterus
Drugs.uterusDrugs.uterus
Drugs.uterus
 
Bleeding Disorder
Bleeding DisorderBleeding Disorder
Bleeding Disorder
 
Blood coagulation cascade
Blood coagulation cascadeBlood coagulation cascade
Blood coagulation cascade
 
Aquasomes: Basic consideration
Aquasomes: Basic considerationAquasomes: Basic consideration
Aquasomes: Basic consideration
 
Drug Design for Pharmacokinetics Problem
Drug Design for Pharmacokinetics ProblemDrug Design for Pharmacokinetics Problem
Drug Design for Pharmacokinetics Problem
 
Liposomes
LiposomesLiposomes
Liposomes
 

Similar to MICROBICIDES

MRC/info4africa KZN Community Forum | May 2012
MRC/info4africa KZN Community Forum | May 2012MRC/info4africa KZN Community Forum | May 2012
MRC/info4africa KZN Community Forum | May 2012info4africa
 
The state of arv based microbicides research, 2010
The state of arv based microbicides research, 2010The state of arv based microbicides research, 2010
The state of arv based microbicides research, 2010gnpplus
 
Project RSP+ "Exploring the Pipeline"
Project RSP+ "Exploring the Pipeline"Project RSP+ "Exploring the Pipeline"
Project RSP+ "Exploring the Pipeline"Jim Pickett
 
Microbicides background
Microbicides backgroundMicrobicides background
Microbicides backgroundsiphojanuary
 

Similar to MICROBICIDES (20)

Journal.pone.0196904 (1)
Journal.pone.0196904 (1)Journal.pone.0196904 (1)
Journal.pone.0196904 (1)
 
Journal.pone.0196904 (1)
Journal.pone.0196904 (1)Journal.pone.0196904 (1)
Journal.pone.0196904 (1)
 
Journal.pone.0196904
Journal.pone.0196904Journal.pone.0196904
Journal.pone.0196904
 
Journal.pone.0196904
Journal.pone.0196904Journal.pone.0196904
Journal.pone.0196904
 
MRC/info4africa KZN Community Forum | May 2012
MRC/info4africa KZN Community Forum | May 2012MRC/info4africa KZN Community Forum | May 2012
MRC/info4africa KZN Community Forum | May 2012
 
The future of_hiv_prevention_prospects_f
The future of_hiv_prevention_prospects_fThe future of_hiv_prevention_prospects_f
The future of_hiv_prevention_prospects_f
 
The future of_hiv_prevention_prospects_f
The future of_hiv_prevention_prospects_fThe future of_hiv_prevention_prospects_f
The future of_hiv_prevention_prospects_f
 
The state of arv based microbicides research, 2010
The state of arv based microbicides research, 2010The state of arv based microbicides research, 2010
The state of arv based microbicides research, 2010
 
MICROBICIDES: Efficacy and Effectiveness
MICROBICIDES: Efficacy and EffectivenessMICROBICIDES: Efficacy and Effectiveness
MICROBICIDES: Efficacy and Effectiveness
 
Nihms757134
Nihms757134Nihms757134
Nihms757134
 
Nihms757134
Nihms757134Nihms757134
Nihms757134
 
Journal.pone.0147743
Journal.pone.0147743Journal.pone.0147743
Journal.pone.0147743
 
Journal.pone.0147743
Journal.pone.0147743Journal.pone.0147743
Journal.pone.0147743
 
Project RSP+ "Exploring the Pipeline"
Project RSP+ "Exploring the Pipeline"Project RSP+ "Exploring the Pipeline"
Project RSP+ "Exploring the Pipeline"
 
Microbicides background
Microbicides backgroundMicrobicides background
Microbicides background
 
Journal.pone.0021528
Journal.pone.0021528Journal.pone.0021528
Journal.pone.0021528
 
Journal.pone.0021528
Journal.pone.0021528Journal.pone.0021528
Journal.pone.0021528
 
Microbicides: A New Hope for HIV/STIs. Global and Local Perspectives
Microbicides: A New Hope for HIV/STIs. Global and Local PerspectivesMicrobicides: A New Hope for HIV/STIs. Global and Local Perspectives
Microbicides: A New Hope for HIV/STIs. Global and Local Perspectives
 
Vaginal ring adherence_in_sub-saharan_africa_expul
Vaginal ring adherence_in_sub-saharan_africa_expulVaginal ring adherence_in_sub-saharan_africa_expul
Vaginal ring adherence_in_sub-saharan_africa_expul
 
Vaginal ring adherence_in_sub-saharan_africa_expul
Vaginal ring adherence_in_sub-saharan_africa_expulVaginal ring adherence_in_sub-saharan_africa_expul
Vaginal ring adherence_in_sub-saharan_africa_expul
 

MICROBICIDES

  • 1. A S E M I N A R P R E S E N T A T I O N B Y B E N J A M I N G O O D L U C K C . 1 2 / 1 0 3 1 M I C R O B I O L O G Y MICROBICIDES
  • 2. INTRODUCTION  HIV most often is spread through unprotected vaginal intercourse, with women twice as likely as men to become infected. (UNAIDS, 2001)  Women represent more than half (52 percent) of all people living with HIV worldwide and account for nearly 60 percent of those with HIV in sub-Saharan Africa. (Rossi and Collins, 2014)  Efforts to promote abstinence, monogamy and the use of male condoms have not been enough to stop the epidemic nor are these approaches practical in many settings.  A vaginal microbicide could potentially give women the means to protect themselves against HIV. 2
  • 3. WHAT ARE MICROBICIDES?  Microbicides are products applied inside the vagina or rectum to protect against sexually transmitted infections (STIs) including human immunodeficiency virus (HIV) through sex (Lerner, 1994)  Microbicides can be formulated as gels, creams, films, or suppositories (Ramjee et al., 2001)  Microbicides may or may not have spermicidal activity (contraceptive effect) (Wilkinson et al., 2002) 3
  • 4. Fig 1. Various Microbicide products, showing; vaginal gel, ring and film. 4
  • 5. BRIEF HISTORY  The idea for a microbicide-like product was first proposed about 25 years ago by reproductive health specialists and advocates who recognized the need for female-controlled HIV prevention methods.  One of the first products considered was the spermicide nonoxynol-9, but clinical trials found it neither safe nor effective against HIV (Wilkinson et al., 2002)  Trials of other so-called first generation microbicides also yielded disappointing results. 5
  • 6. HOW DO THEY WORK?  There are different ways in which microbicides act to prevent infection with genital pathogens.  Some microbicides (e.g Carraguard®, Cyanoviran®, cellulose sulphate, PRO 2000®) provide a physical barrier that keeps HIV and other pathogens from reaching the target cells.  Another class of microbicides (e.g. Acidform®, BufferGel®) act by enhancing the natural vaginal defence mechanisms by maintaining an acidic pH, which protects the vagina. 6
  • 7. Cont.  C31G and octoxynol-9 kill or disable pathogens by stripping them of their outer covering.  Another class of products e.g tenofovir (PMPA) acts by preventing replication of the virus after it has entered the cell (Karim, 2010) 7
  • 9. MICROBICIDES CLINICAL TRIALS  There are three phases of clinical trials that a potential mircobicide must pass through before it is judged effective and safe. 1. Phase I involves a small number of volunteers to test the safety of various doses 2. Phase II involves hundreds of volunteers to further assess safety and, in some cases, positive responses 3. Phase III involves thousands of volunteers to test safety and effectiveness 4. The Phase IIb trial, a recent innovation, is a larger variant of the Phase II trial.  Phase I tends to last between twelve and eighteen months, whereas the final phase can take up to three or four years (Microbicides Trials Network, 2013) 9
  • 10. Fig.3: Process of Testing 10
  • 11.  There are several different microbicide candidates currently being studied. As of May 2013 there were 11 phase I trials, 1 phase I/II trial, and 4 phase III trials. The current status of ongoing microbicide trials can be found here (MTN, 2013)  IPM027 (The Ring Study)  MTN 020 (ASPIRE)  CAPRISA 008  FACTS 001 11
  • 12. Product Clinical Trials Country Case Study Duration Tenofovir Vaginal gel CAPRISA 004 FACTS 001 (PhaseIII) CAPRISA 008 (PhaseIIb) South Africa South Africa South Africa 889 women 2900 women 889 women Completed 2011-2015 2011-2015 Vaginal Rings ASPIRE(MTN-020) (PhaseIII) The Ring Study (IPM 027) (PhaseIII) MTN-013/IPM 026 (PhaseI) MTN-023/IPM 30 and MTN- 024/IPM31 (PhaseI) Malawi, Uganda, South Africa and Zimbabwe South Africa and Uganda United States Malawi, Uganda, South Africa and Zimbabwe 3476 women 1650 women Unknown Adolescent girls and post- menopausal women 2012-2015 2012- 2015/2016 Completed 2012-2016 Table 1: Current Microbicides Clinical Trials 12
  • 13.  Which microbicide trials have recently ended?  CAPRISA 004  This phase IIb trial assessed the safety and effectiveness of tenofovir gel in 900 HIV-negative, sexually active women between the ages of 18 and 40 years, living in South Africa. Results for this trial were announced in July, 2010.  The statistically significant results found: 1. Tenofovir gel reduced the risk of HIV infection by 39 percent overall 2. Protective effect increased to 54 percent among women with high gel adherence  The CAPRISA 004 study was the first to provide proof of concept for microbicides. The study found statistically significant results showing microbicides can prevent the sexual transmission of HIV (MTN, 2011) 13
  • 14.  Researchers now are evaluating microbicide products that incorporate ARV drugs, including ARVs commonly used in HIV treatment.  The most studied ARV-based microbicide is tenofovir gel, which was found safe and effective in reducing HIV risk in women who used it before and after vaginal sex in a study called CAPRISA 004 but not effective in another study known as VOICE, which was designed to evaluate its daily use (as well as daily use of either the oral ARV tablet tenofovir or Truvada). TENOFOVIR/VAGINAL GELS 14
  • 16. Fig.5: Picture showing the oral ARV tablet and the tenovovir vaginal gel L-R: Left: Oral ARV tablet (tenofovir) Right: Tenofovir Vaginal gel 16
  • 17.  As an alternative to vaginal gels, researchers are evaluating other formulations, including paper-thin quickdissolve vaginal films that after insertion would melt away and disperse active drug to protect cells in the vagina.  Films are in the early phases of clinical testing. VAGINAL FILMS 17
  • 18. Fig.6: A paper-thin quick dissolving vaginal film 18
  • 19. VAGINAL RINGS  Vaginal rings, flexible products that fit comfortably inside the vagina and provide sustained delivery of drugs over a period of time, are being tested in both early phase studies and Phase III trials.  Vaginal ring products are already used in many countries to deliver hormonal contraception.  For HIV prevention, the dapivirine ring is the first vaginal ring – and the first HIV-prevention product intended for monthly use – to enter efficacy testing. 19
  • 20. Cont.  Vaginal rings containing both an ARV and a contraceptive are also being developed that would potentially provide women both HIV protection and contraception in a single product. Phase I trials began in 2014. 20
  • 22. RECTAL MICROBICIDES  Although the majority of microbicide research has focused on products to prevent HIV through vaginal sex, anal sex is common among men who have sex with men (MSM) and practiced by women around the world.  According to some estimates, the risk of infection through anal sex is 20 times greater than vaginal sex because the rectal lining, the mucosa, is thinner and much more fragile than the lining of the vagina. 22
  • 23. CONT.  An important first step to the development of rectal microbicides has been evaluating the rectal safety of microbicides originally formulated as vaginal gels, in particular, tenofovir gel.  An early study found that the vaginal formulation of tenofovir gel caused gastrointestinal side effects when used in the rectum, so researchers tested a reformulated version of the gel with less glycerin in a follow-up study called MTN-007.  That study found the reduced glycerin gel safe, acceptable and better tolerated than the vaginal gel when used in the rectum. 23
  • 24. HOW IS IT FUNDED?  In 2011 around $186 million was invested in microbicide research and development (a 25 percent decrease on the previous year).  This decline has been associated with the cycle of funding disbursement, rather than a decline in investment.  About 95 percent of this money came from the public sector, 5 percent came from the philanthropic sector, and <1 percent was accounted for by commercial companies (only $1 million).  To ensure microbicides a  re available to women in low- and middle-income countries, profit margins would need to be low (UNAIDS, 2008) 24
  • 25. CONCLUSION  A safe and effective microbicide has potential to become a key method of HIV prevention. As the trials above demonstrate, microbicide research and development brings us ever closer to having a successful candidate.  Any successful product would have to undergo review and licensing by regulatory agencies before becoming available to the public.  It would take time to work out the best formulation and dosage; find a suitable delivery method; and distribute the product. 25
  • 26. REFERENCES  HIV Vaccines and Microbicides Resource Tracking Working Group (2012) Investing to End the AIDS Epidemic: A New Era for HIV Prevention Research & Development  Karim, Q.A. (2010) ' Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women', Science 329(5996)  Lerner S., (1994). Microbicides: a woman-controlled HIV prevention method in the making. SIECUS : 22:10-3.  Lisa Rossi and Clare Collins. 2014. “ Fact sheet about microbicides”. Microbicides Trials Network, www.mtnstopshiv.org  Microbicide Trials Network, (2011). MTN Statement on Decision to Discontinue Use of Tenofovir Gel in VOICE, a Major HIV Prevention Study in Women  Microbicide Trials Network, (2013). Fact Sheet: Understanding the results of VOICE 26
  • 27. Cont.  UNAIDS, (1996). International Working Group on Vaginal Microbicides, Recommendations for the development of microbicides. AIDS, 10:1-6.  Ramjee G, Gouws E, Andrews A, Myer L, Weber A.E., (2001). The acceptability of a vaginal microbicides among South African men. International Family planning Perspectives, 27:164-170.  UNAIDS, (2001). AIDS epidemic update: Joint United Nations Programme on HIV/AIDS and the World Health Organization.  UNAIDS, (2008). Microbicides: challenges to development and distribution.  Wilkinson D, Tholandi M, Ramjee G, Rutherford GW., (2002). Nonoxynol- 9 spermicide for prevention of vaginally acquired HIV and other sexually transmitted infections: systematic review and meta-analysis of randomised controlled trials including more than 5000 women. Lancet Infectious Diseases; 2:613-617  World Health Organization, (2009). Regulatory issues in microbicide development. 27